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| INTRODUC TI ON
Alzheimer's disease (AD) is an insidious, progressive, and irreversible neurodegenerative disease that is currently considered to start affecting the brain about 50 years before full disease manifestation (Braak stage V). 1 As the leading cause of dementia, accounting for 60-70% of all dementia cases, AD affects about 5.7 Americans 2 and over 30 million people worldwide. 3 According to the "World Alzheimer Report 2018," 3 there is a new case of dementia developed every 3 seconds around the world and 66% of dementia patients live in low-and middle-income countries.
Alzheimer's disease is the only major disease that currently has no effective ways to cure, reverse, arrest, or even slow down disease progression once symptoms start. Despite advances made in understanding the underlying pathophysiology of AD, treatment for this disease has progressed little since AD was first reported by Alois Alzheimer in 1906. 4 At present only five medications out of hundreds of agents Developed on a continuum, AD begins with a clinically asymptomatic preclinical phase and continues through an early phase with mild cognitive impairment (MCI; or prodromal AD) affecting the ability to store new information into episodic memory and a progressive loss of old memories before leading eventually to fully manifested dementia. There are three types of cognitive assessment instruments for the screening of AD: (1) instruments that are administered by a health-care provider; (2) instruments that are self-administered;
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| THE BENEFIT OF EARLY DETECTION OF AD
and (3) instruments for informant reporting. 17 This review will briefly summarize the currently available health-provider-administered instruments and status of a self-administered screening instrument that has the potential to (1) detect early AD-related cognitive changes before symptoms start and (2) assess disease progression.
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| AD SCREENING IN S TRUMENTS ADMINIS TERED BY A HE ALTH PROVIDER
The following should be considered when choosing an AD screening instrument or complementary instruments: With the realization that AD develops on a continuum over a long period of time potentially stretching back over five decades before the manifestation of full-onset dementia, an instrument that could repeatedly measure episodic memory and other cognitive functions, such as attention, execution, and response speed, longitudinally and in different contexts (home versus health-care center) worldwide, is in great demand.
| CURRENT S TATUS OF AD SCREENING IN S TRUMENTS THAT C AN B E S ELF-ADMINIS TERED
Accurate measurement of AD from its preclinical phase through its progression to mild dementia is necessary for identifying AD early, TA B L E 1 Recommended screening instruments for Alzheimer's disease (AD) screen recommended by De Roeck et al but a robust tool has not yet been identified for this purpose. As AD is predominantly a disorder of neuroplasticity, the central issue becomes identifying an instrument or instruments that can accurately probe AD-specific changes across all stages of AD. It is also critical to be able to measure these changes using metrics universal to the population yet unique to the individual over time, to detect the interaction between AD and sequelae of normal aging, and to assess where a subject lies on the continuum of early cognitive decline associated with AD relative to normal aging. Such an instrument or instruments would more properly ensure adequate enrollment, protocol adherence, and retention of subjects likely to benefit from therapeutic interventions and enable design of treatments and assessments of their effectiveness. Further studies are needed to determine:
1. MemTrax's precision, particularly in distinguishing common agerelated effects on cognition, including learning and memory, from the longitudinal changes associated with early AD. 
| FUTURE D IREC TI ON S
For clinical and societal acceptance, there should be a "costworthiness" analysis for determining test benefit for early AD detection and early detection instruments. When screening for AD should start is an important issue that requires future consideration. This determination largely depends on how early before onset of symptoms a clinically relevant deficit can be detected. There are studies indicating that the first detectable cognitive changes associated with the development of dementia occur 10 years before onset of clinically diagnosable symptoms. 34, 35 Neurofibrillary studies at autopsy trace AD back to about 50 years and may even extend into adolescence. 1 It has yet to be determined whether these early changes can be translated into detectable markers of cognitive dysfunction. Certainly, current instruments lack this level of sensitivity. The question then is whether future, substantially more sensitive, tests can identify much earlier changes in cognitive function related to AD and with adequate specificity. With the precision of MemTrax, particularly with multiple testing frequently repeated over an extended period, it could be possible for the first time to track the memory and cognitive changes in individuals at risk over a decade before clinically apparent cognitive impairment develops. Data on a variety of epidemiological factors (eg, obesity, hypertension, post-traumatic stress disorder, traumatic brain injury) suggest that some individuals are already predisposed to memory impairment and/or to developing dementia and AD in their forties or earlier. 36, 37 These widespread populations at risk demonstrate a clear need to identify and determine the earliest cognitive markers of early neurodegeneration and AD with suitable screening instruments.
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